Aaron C. Ermel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aaron C. Ermel has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Darron R. Brown
Indiana University School of Medicine
4 shared publications - Doreen Ramogola-Masire
Faculty of Medicine, University of Botswana, Gaborone, Botswana
2 shared publications - Eduardo Luis Franco
Division of Cancer Epidemiology, McGill University, Montreal, QC H4A 3T2, Canada
2 shared publications - Lili Ding
Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
2 shared publications - Nicola M. Zetola
Botswana-UPenn Partnership, Gaborone, Botswana
2 shared publications - Yan Tong
Indiana University School of Medicine, Department of Biostatistics & Health Data Science, Indianapolis, IN, United States
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 117 (1) , 117687
Diagnostic accuracy of a multiplex nucleic acid amplification test for detecting gastrointestinal bacterial pathogens: A multicenter clinical study
- 6 October 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 117 (1) , 117687
Open AccessDiagnostic accuracy of a multiplex nucleic acid amplification test for detecting gastrointestinal bacterial pathogens: A multicenter clinical study
- Open Access
- 25 November 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (4) , 786-799
Development of an HPV 16 rapid test founded in user-centered design with primary care clinicians
Despite effective screening modalities, cervical cancer remains a leading cause of cancer-related death among women in the United States aged 20 to 39 years old, and incidence is rising in women aged 30–44 years old. Up to 25% of patients who are screened for cervical cancer by testing for human papillomavirus (HPV) do not receive necessary follow-up care with current laboratory-based testing. Applying a user-centered design approach, we surveyed and interviewed practicing clinicians to establish the use case, value proposition, and user requirements of a cervical cancer screening test for use in Indiana, USA. Insights from these stakeholders directly informed design specifications for a point-of-care HPV test capable of providing same-visit results to improve patient follow-up and retention. Guided by these requirements, we designed an isothermal nucleic acid amplification platform suitable for outpatient clinics. The test accepts swabbed endocervical cells, amplifies HPV16 L1 DNA via recombinase polymerase amplification, and provides results within 40 minutes on a lateral flow assay. Further, the test achieves a clinically relevant limit of detection of 1000 HPV 16 copies per reaction and verifies swabbing technique and test operation with a sample adequacy control. The test operation was designed for a minimally-trained user and decreases time-sensitive steps that would interfere with clinical flow. By integrating clinician input to inform development decisions, our device is uniquely tailored to meet the context-specific needs of primary care clinics. This work exemplifies how user-centered design can yield novel diagnostic technologies with greater clinical impact and adoption potential.
- 25 November 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (4) , 786-799
Open AccessDevelopment of an HPV 16 rapid test founded in user-centered design with primary care clinicians
Despite effective screening modalities, cervical cancer remains a leading cause of cancer-related death among women in the United States aged 20 to 39 years old, and incidence is rising in women aged 30–44 years old. Up to 25% of patients who are screened for cervical cancer by testing for human papillomavirus (HPV) do not receive necessary follow-up care with current laboratory-based testing. Applying a user-centered design approach, we surveyed and interviewed practicing clinicians to establish the use case, value proposition, and user requirements of a cervical cancer screening test for use in Indiana, USA. Insights from these stakeholders directly informed design specifications for a point-of-care HPV test capable of providing same-visit results to improve patient follow-up and retention. Guided by these requirements, we designed an isothermal nucleic acid amplification platform suitable for outpatient clinics. The test accepts swabbed endocervical cells, amplifies HPV16 L1 DNA via recombinase polymerase amplification, and provides results within 40 minutes on a lateral flow assay. Further, the test achieves a clinically relevant limit of detection of 1000 HPV 16 copies per reaction and verifies swabbing technique and test operation with a sample adequacy control. The test operation was designed for a minimally-trained user and decreases time-sensitive steps that would interfere with clinical flow. By integrating clinician input to inform development decisions, our device is uniquely tailored to meet the context-specific needs of primary care clinics. This work exemplifies how user-centered design can yield novel diagnostic technologies with greater clinical impact and adoption potential.
- 17 March 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (2) , 412-416
Noninvasive Monitoring of Humoral Immune Responses in Men With Acute Chlamydia trachomatis Urethral Infection Using First-Catch Urine
We investigated the relationship between Chlamydia trachomatis load and anti-chlamydial antibody using first-catch urine from 108 men with nongonococcal urethritis. Men who reported prior chlamydia had elevated anti-chlamydial IgA and lower loads, but load and antibody were not correlated. Load positively correlated with anti-chlamydial IgA only in men who did not self-report prior chlamydia and with anti-chlamydial IgG regardless of infection history. Overall, we document genotype-specific differences in C. trachomatis load, clarify that partial immunity associated with repeat infections is not antibody mediated, and demonstrate a method to monitor humoral immune responses to C. trachomatis in men using noninvasively collected urine.
- 17 March 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (2) , 412-416
Noninvasive Monitoring of Humoral Immune Responses in Men With Acute Chlamydia trachomatis Urethral Infection Using First-Catch Urine
We investigated the relationship between Chlamydia trachomatis load and anti-chlamydial antibody using first-catch urine from 108 men with nongonococcal urethritis. Men who reported prior chlamydia had elevated anti-chlamydial IgA and lower loads, but load and antibody were not correlated. Load positively correlated with anti-chlamydial IgA only in men who did not self-report prior chlamydia and with anti-chlamydial IgG regardless of infection history. Overall, we document genotype-specific differences in C. trachomatis load, clarify that partial immunity associated with repeat infections is not antibody mediated, and demonstrate a method to monitor humoral immune responses to C. trachomatis in men using noninvasively collected urine.
- Open Access
- 27 April 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-8
A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women
Cervical cancer is caused by oncogenic human papillomaviruses (HPV) and is one of the most common malignancies in women living in sub-Saharan Africa. Women infected with the human immunodeficiency virus (HIV) have a higher incidence of cervical cancer, but the full impact on HPV detection is not well understood, and associations of biological and behavioral factors with oncogenic HPV detection have not been fully examined. Therefore, a study was initiated to investigate factors that are associated with oncogenic HPV detection in Kenyan women. Women without cervical dysplasia were enrolled in a longitudinal study. Data from enrollment are presented as a cross-sectional analysis. Demographic and behavioral data was collected, and HPV typing was performed on cervical swabs. HIV-uninfected women (n = 105) and HIV-infected women (n = 115) were compared for demographic and behavioral characteristics using t-tests, Chi-square tests, Wilcoxon sum rank tests or Fisher’s exact tests, and for HPV detection using logistic regression or negative binomial models adjusted for demographic and behavioral characteristics using SAS 9.4 software. Compared to HIV-uninfected women, HIV-infected women were older, had more lifetime sexual partners, were less likely to be married, were more likely to regularly use condoms, and were more likely to have detection of HPV 16, other oncogenic HPV types, and multiple oncogenic types. In addition to HIV, more lifetime sexual partners was associated with a higher number of oncogenic HPV types (aIRR 1.007, 95% CI 1.007–1.012). Greater travel distance to the clinic was associated with increased HPV detection (aOR for detection of ≥ 2 HPV types: 3.212, 95% CI 1.206–8.552). Older age (aOR for HPV 16 detection: 0.871, 95% CI 0.764–0.993) and more lifetime pregnancies (aOR for detection of oncogenic HPV types: 0.706, 95% CI, 0.565–0.883) were associated with reduced detection. HIV infection, more lifetime sexual partners, and greater distance to health-care were associated with a higher risk of oncogenic HPV detection, in spite of ART use in those who were HIV-infected. Counseling of women about sexual practices, improved access to health-care facilities, and vaccination against HPV are all potentially important in reducing oncogenic HPV infections.
- 27 April 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-8
Open AccessA cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women
Cervical cancer is caused by oncogenic human papillomaviruses (HPV) and is one of the most common malignancies in women living in sub-Saharan Africa. Women infected with the human immunodeficiency virus (HIV) have a higher incidence of cervical cancer, but the full impact on HPV detection is not well understood, and associations of biological and behavioral factors with oncogenic HPV detection have not been fully examined. Therefore, a study was initiated to investigate factors that are associated with oncogenic HPV detection in Kenyan women. Women without cervical dysplasia were enrolled in a longitudinal study. Data from enrollment are presented as a cross-sectional analysis. Demographic and behavioral data was collected, and HPV typing was performed on cervical swabs. HIV-uninfected women (n = 105) and HIV-infected women (n = 115) were compared for demographic and behavioral characteristics using t-tests, Chi-square tests, Wilcoxon sum rank tests or Fisher’s exact tests, and for HPV detection using logistic regression or negative binomial models adjusted for demographic and behavioral characteristics using SAS 9.4 software. Compared to HIV-uninfected women, HIV-infected women were older, had more lifetime sexual partners, were less likely to be married, were more likely to regularly use condoms, and were more likely to have detection of HPV 16, other oncogenic HPV types, and multiple oncogenic types. In addition to HIV, more lifetime sexual partners was associated with a higher number of oncogenic HPV types (aIRR 1.007, 95% CI 1.007–1.012). Greater travel distance to the clinic was associated with increased HPV detection (aOR for detection of ≥ 2 HPV types: 3.212, 95% CI 1.206–8.552). Older age (aOR for HPV 16 detection: 0.871, 95% CI 0.764–0.993) and more lifetime pregnancies (aOR for detection of oncogenic HPV types: 0.706, 95% CI, 0.565–0.883) were associated with reduced detection. HIV infection, more lifetime sexual partners, and greater distance to health-care were associated with a higher risk of oncogenic HPV detection, in spite of ART use in those who were HIV-infected. Counseling of women about sexual practices, improved access to health-care facilities, and vaccination against HPV are all potentially important in reducing oncogenic HPV infections.
- Open Access
- 11 November 2016
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 11 (1) , 1-9
Invasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications
More deaths occur in African women from invasive cervical cancer (ICC) than from any other malignancy. ICC is caused by infection with oncogenic types of human papillomavirus (HPV). Co-infection with the human immunodeficiency virus (HIV) accelerates the natural history of ICC, and may influence the HPV type distribution. Because HPV vaccines are available, this malignancy is theoretically preventable, but the vaccines are largely type-specific in protection against infection. Data on specific HPV types causing ICC in African women is limited, and many studies utilized swab samples rather than actual cancer tissue. A previous study using archived, ICC tissue from women in Botswana identified an unusual HPV type distribution. A similar study was therefore performed in a second sub-Saharan country to provide additional information on the HPV type distribution in ICC. Archived, formalin-fixed, paraffin-embedded ICCs were acquired from women in the United States, Kenya, or Botswana. DNA was extracted and HPV genotyping performed by Roche Linear Array. HIV sequences were identified in ICCs by PCR. HPV types 16 or 18 (HPV 16/18) were identified in 93.5 % of HPV-positive ICCs from the U.S., 93.8 % from Kenya, and 61.8 % from Botswana (p < 0.0001). Non-HPV 16/18 types were detected in 10.9 % of HPV-positive cancers from the U.S., 17.2 % from Kenya, and 47.8 % from Botswana (p < 0.0001). HIV was detected in 2.2, 31.5, and 32.4 % from ICCs from the U.S., Kenya, or Botswana, respectively (p = 0.0002). The distribution of HPV types was not significantly different between HIVinfected or HIV-uninfected women. The percentages of ICCs theoretically covered by the bivalent/quadrivalent HPV vaccines were 93.5, 93.9, and 61.8 % from the U.S., Kenya and Botswana, respectively, and increased to 100, 98, and 77.8 % for the nanovalent vaccine. HPV 16/18 caused most ICCs from the U.S. and western Kenya. Fewer ICCs contained HPV 16/18 in Botswana. HIV co-infection did not influence the HPV type distribution in ICCs from African women from the two countries. Available HPV vaccines should provide protection against most ICCs in the U.S. and Kenya. The recently developed nanovalent vaccine may be more suitable for countries where non-HPV 16/18 types are frequently detected in ICC.
- 11 November 2016
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 11 (1) , 1-9
Open AccessInvasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications
More deaths occur in African women from invasive cervical cancer (ICC) than from any other malignancy. ICC is caused by infection with oncogenic types of human papillomavirus (HPV). Co-infection with the human immunodeficiency virus (HIV) accelerates the natural history of ICC, and may influence the HPV type distribution. Because HPV vaccines are available, this malignancy is theoretically preventable, but the vaccines are largely type-specific in protection against infection. Data on specific HPV types causing ICC in African women is limited, and many studies utilized swab samples rather than actual cancer tissue. A previous study using archived, ICC tissue from women in Botswana identified an unusual HPV type distribution. A similar study was therefore performed in a second sub-Saharan country to provide additional information on the HPV type distribution in ICC. Archived, formalin-fixed, paraffin-embedded ICCs were acquired from women in the United States, Kenya, or Botswana. DNA was extracted and HPV genotyping performed by Roche Linear Array. HIV sequences were identified in ICCs by PCR. HPV types 16 or 18 (HPV 16/18) were identified in 93.5 % of HPV-positive ICCs from the U.S., 93.8 % from Kenya, and 61.8 % from Botswana (p < 0.0001). Non-HPV 16/18 types were detected in 10.9 % of HPV-positive cancers from the U.S., 17.2 % from Kenya, and 47.8 % from Botswana (p < 0.0001). HIV was detected in 2.2, 31.5, and 32.4 % from ICCs from the U.S., Kenya, or Botswana, respectively (p = 0.0002). The distribution of HPV types was not significantly different between HIVinfected or HIV-uninfected women. The percentages of ICCs theoretically covered by the bivalent/quadrivalent HPV vaccines were 93.5, 93.9, and 61.8 % from the U.S., Kenya and Botswana, respectively, and increased to 100, 98, and 77.8 % for the nanovalent vaccine. HPV 16/18 caused most ICCs from the U.S. and western Kenya. Fewer ICCs contained HPV 16/18 in Botswana. HIV co-infection did not influence the HPV type distribution in ICCs from African women from the two countries. Available HPV vaccines should provide protection against most ICCs in the U.S. and Kenya. The recently developed nanovalent vaccine may be more suitable for countries where non-HPV 16/18 types are frequently detected in ICC.
- 2 August 2015
- Published by Springer Nature
- p. 25-42
Behavioral Correlates of HPV-Associated Oropharyngeal Squamous Cell Carcinomas
- 2 August 2015
- Published by Springer Nature
- p. 25-42
Behavioral Correlates of HPV-Associated Oropharyngeal Squamous Cell Carcinomas
- Open Access
- 8 July 2014
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 9 (1) , 22
Invasive cervical cancers from women living in the United States or Botswana: differences in human papillomavirus type distribution
Cervical cancer is the primary cause of cancer-related deaths in women living in Botswana.
- 8 July 2014
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 9 (1) , 22
Open AccessInvasive cervical cancers from women living in the United States or Botswana: differences in human papillomavirus type distribution
Cervical cancer is the primary cause of cancer-related deaths in women living in Botswana.